ストックスクリーナーアプリを入手
10.28
3.42%
0.34
前日終値:
$9.94
開ける：
$9.95
24時間の取引高:
688.86K
Relative Volume:
0.75
時価総額：
$894.82M
収益：
-
当期純損益:
$-106.81M
株価収益率:
-3.1041
EPS:
-3.3117
ネットキャッシュフロー:
$-8.40M
1週間 パフォーマンス:
+6.09%
1か月 パフォーマンス:
+22.38%
6か月 パフォーマンス:
-1.15%
1年 パフォーマンス:
-26.31%
1日の値動き範囲:
$9.92
$10.38
1週間の範囲:
$9.47
$10.38
52週間の値動き範囲:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
IMNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.28 | 865.23M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Lake Street | Buy |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-04-30 | 開始されました | JP Morgan | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-01-29 | 開始されました | Leerink Partners | Outperform |
| 2023-12-19 | 開始されました | Wedbush | Outperform |
| 2021-10-29 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Immunome Inc (IMNM) 最新ニュース
Immunome Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 Breakouts & High Win Rate Trade Tips - metal.it
What momentum shifts mean for Immunome Inc.Quarterly Earnings Report & Reliable Price Breakout Signals - Newser
Can Immunome Inc. maintain its current growth rate2025 Support & Resistance & Verified Entry Point Detection - sisa-n.com
Should you hold or exit Immunome Inc. nowJuly 2025 Spike Watch & Daily Chart Pattern Signal Reports - Newser
What’s next for Immunome Inc. stock priceJuly 2025 Patterns & Stock Market Timing Techniques - Newser
When is the best time to exit Immunome Inc.July 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Using Ichimoku Cloud for Immunome Inc. technicals2025 Stock Rankings & Daily Entry Point Trade Alerts - Newser
Will Immunome Inc. continue its uptrend2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
Is a relief rally coming for Immunome Inc. holdersM&A Rumor & Fast Exit Strategy with Risk Control - Newser
Will Immunome Inc. bounce back from current supportTrade Analysis Report & Verified Swing Trading Watchlists - Newser
Will earnings trigger a reversal in Immunome Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Chart based analysis of Immunome Inc. trendsJuly 2025 Price Swings & Short-Term Swing Trade Alerts - Newser
Multi asset correlation models including Immunome Inc.2025 Big Picture & Scalable Portfolio Growth Ideas - Newser
Will Immunome Inc. stock benefit from AI tech trendsWeekly Gains Report & Verified Momentum Stock Alerts - Newser
How to forecast Immunome Inc. trends using time seriesTrade Risk Report & Fast Exit/Entry Strategy Plans - Newser
Fibonacci Retracement Aligns with Support in Immunome Inc.July 2025 EndofMonth & Community Verified Trade Signals - thegnnews.com
Will Immunome Inc. stock recover after recent dropQuarterly Profit Summary & Real-Time Buy Zone Alerts - Newser
What makes Immunome Inc. stock attractive to long term investorsQuarterly Growth Report & AI Forecast for Swing Trade Picks - Newser
Trapped Investors in Immunome Inc. Await Breakout SignalWeekly Profit Recap & Daily Entry Point Trade Alerts - sundaytimes.kr
Sectors Driving Future Growth for Immunome Inc. StockJuly 2025 Fed Impact & Advanced Technical Analysis Signals - Newser
Trendlines Converge — Decision Point for Immunome Inc.July 2025 Breakouts & High Accuracy Buy Signal Tips - sundaytimes.kr
Short interest data insights for Immunome Inc.Weekly Risk Summary & Daily Profit Focused Screening - Newser
Immunome's Undervalued Gamma Secretase Inhibitor Pipeline in Light of SpringWorks' Merck Acquisition - AInvest
Immunome's SpringWorks Buyout Highlights Upside Potential - AInvest
Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha
What makes Immunome Inc. stock price move sharplyReal-Time AI Generated Market Forecast - Newser
Immunome Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quant Tools Rank Immunome Inc. as High Risk High RewardChart Based Entries - beatles.ru
Wedbush Comments on Immunome’s Q3 Earnings (NASDAQ:IMNM) - Defense World
Research Analysts Offer Predictions for Immunome Q3 Earnings - Defense World
What recovery options are there for Immunome Inc.5-Year Price Trend Summary and Analysis - Newser
How Immunome Inc. stock performs during market volatilityLong-Term Allocation Strategy Summary Breakdown - Newser
Is Immunome Inc. benefiting from innovation trendsSmart Portfolio Allocation - newsyoung.net
A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38 - 富途牛牛
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating - 富途牛牛
Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73% - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance
Immunome, Inc. (NASDAQ:IMNM) Given Average Rating of “Buy” by Brokerages - Defense World
Immunome 2025 Q2 Earnings Wider Net Loss Despite Revenue Surge - AInvest
New Product Launches: Will They Boost Immunome Inc. Stock in 2025Growth Focused Entry Plan Suggestions Issued - beatles.ru
JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain - GuruFocus
Immunome 2025 Q2 Earnings Narrowed EPS Loss, 69.8% Revenue Growth - AInvest
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Immunome Advances Cancer Therapy Pipeline Amid Financial Loss - TipRanks
Does Immunome Inc. qualify in momentum factor screeningFree Triple Return Setup with Risk Control - Newser
Immunome Inc (IMNM) 財務データ
収益
当期純利益
現金流量
EPS
Immunome Inc (IMNM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):